AnaptysBio (ANAB)

Executive Summary

AnaptysBio is a clinical-stage biotechnology company focused on developing best-in-class therapeutic antibodies for autoimmune and inflammatory diseases. Its lead pipeline candidate, rosnilimab (a PD-1 agonist), is being evaluated in Phase 2 trials for ulcerative colitis (UC) and rheumatoid arthritis (RA), with the UC trial expected to complete in May 2026. The company employs a dual strategy of proprietary antibody development alongside a portfolio of out-licensed, royalty-generating assets. A key corporate catalyst is the planned separation into two distinct public companies by the end of 2026, aimed at unlocking shareholder value. With a market capitalization of approximately $1.5 billion and multiple clinical data readouts anticipated, AnaptysBio represents a high-risk, high-reward opportunity in the biotech space.

Upcoming Catalysts (preview)

• Q3 2026Rosnilimab Phase 2 Ulcerative Colitis Data Readout45% success
• Q4 2026Completion of Corporate Separation into Two Entities70% success